Japans Kowa says ivermectin effective against Omicron in phase III trial – Reuters

Test tube with Corona virus name label is seen in this illustration taken on January 29, 2020. REUTERS/Dado Ruvic

TOKYO, Jan 31 (Reuters) – Japanese trading and pharmaceutical company Kowa Co Ltd (7807.T) said on Monday anti-parasite drug ivermectin has an “antiviral effect” against Omicron and other variants of COVID-19 as Phase III clinical trials continue.

The company did not provide further details.

The firm has been working with Kitasato University, a medical university in Tokyo, on testing the drug which is used to treat parasites in animals and humans, as a potential treatment for COVID-19.

Clinical trials are ongoing but promotion of the drug as a COVID-19 treatment has generated controversy.

The drug is not approved for treatment of COVID-19 in Japan and the U.S. Federal Drug Administration, the World Health Organization and the EU drug regulator have warned against its use.

Reporting by Sam Nussey and Rocky Swift;
Editing by Tomasz Janowskiand Louise Heavens

Our Standards: The Thomson Reuters Trust Principles.